Presidio Pharmaceuticals

About:

Presidio Pharmaceuticals discovers, develops and commercializes novel therapeutics for viral infections, including HCV and HIV.

Website: http://www.presidiopharma.com

Top Investors: New Leaf Venture Partners, Bay City Capital, Baker Brothers Advisors LLC, Panorama Capital, Ventures West

Description:

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures LLC.

Total Funding Amount:

$100M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2006-01-01

Contact Email:

contact(AT)presidiopharma.com

Founders:

Johnno Surdam, Omar K. Haffar

Number of Employees:

11-50

Last Funding Date:

2014-06-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai